Unexpected Protective Role of Thrombosis in Lung Injury via Endothelial Alox15.

Summary

In murine sepsis-induced ALI/ARDS models, mild pulmonary thrombosis reduced endothelial apoptosis, lung injury, and mortality via sustained endothelial Alox15, whereas severe thrombosis or thrombocytopenia worsened injury. Endothelial Alox15 overexpression and ALOX15-dependent lipids mitigated injury, nominating ALOX15/lipid mediators as therapeutic targets.

Key Findings

• Mild pulmonary thrombosis reduced endothelial apoptosis, ALI severity, and mortality via sustained endothelial Alox15 expression.
• Severe pulmonary thrombosis or thrombocytopenia augmented sepsis-induced ALI.
• Endothelial Alox15 overexpression and ALOX15-dependent lipid rescue experiments mitigated lung injury, suggesting therapeutic targeting.

Clinical Implications

While not practice-changing yet, the data caution against indiscriminate anticoagulation in sepsis-related ARDS and support exploring ALOX15 upregulation or lipid mediator therapy, particularly in patients with thrombocytopenia or extensive thrombosis.

Limitations

• Findings are preclinical in murine models; human validation is lacking
• Potential off-target effects of nanoparticle gene delivery not fully characterized

Future Directions

Validate ALOX15 pathway and lipid mediators in human ARDS samples; stratify patients by thrombosis/platelet status; develop pharmacologic ALOX15 agonists or lipid-based therapeutics; design early-phase trials with biomarker endpoints.